60 acast.com The Leading Strand https://shows.acast.com/the-leading-strand en Mary Ann Liebert, Inc., publishers scholarly publishing ,academic journals,biotechnology,deep science Mary Ann Liebert, Inc., publishers Hosted by Jonathan Grinstein, PhD, The Leading Strand is a cutting-edge podcast series featuring candid conversations with pioneers of biotechnology. The Leading Strand ventures through this vast landscape of innovation, using the catalog of Mary Ann Liebert peer-reviewed journals (established in 1980) as a guide. Each episode features a biotech topic matching one of the over 100 Mary Ann Liebert journals -- from health and medicine, like Human Gene Therapy, to budding fields, like Astrobiology -- that will be explored with members of the biotech community and the editors in chief of these journals.



Hosted on Acast. See acast.com/privacy for more information.

]]> Hosted by Jonathan Grinstein, PhD, The Leading Strand is a cutting-edge podcast series featuring candid conversations with pioneers of biotechnology. The Leading Strand ventures through this vast landscape of innovation, using the catalog of Mary Ann Liebert peer-reviewed journals (established in 1980) as a guide. Each episode features a biotech topic matching one of the over 100 Mary Ann Liebert journals -- from health and medicine, like Human Gene Therapy, to budding fields, like Astrobiology -- that will be explored with members of the biotech community and the editors in chief of these journals.



Hosted on Acast. See acast.com/privacy for more information.

]]> false Mary Ann Liebert, Inc., publishers info+64d6996307d13c001124097d@mg-eu.acast.com 64d6996307d13c001124097d the-leading-strand episodic https://assets.pippa.io/shows/cover/1691785540141-d839032598af94cfaac6f2547a3ccad9.jpeg https://shows.acast.com/the-leading-strand The Leading Strand Not Your Average PI Not Your Average PI Fri, 11 Aug 2023 20:41:49 GMT 35:48 64d69d0d07d13c001124b389 false https://shows.acast.com/the-leading-strand/episodes/not-your-average-pi 64d69d0d07d13c001124b389 64d6996307d13c001124097d not-your-average-pi Forensic genomics, next-generation sequencing, computational biology, population genetics, biomarker discovery full 1 4 In this episode, Nicole Novroski, PhD, examines the up-and-coming field of forensic genomics, covering everything from current and controversial forensic genomics research topics to mistakes and misconceptions about the field brought on by television and film and to some of the field’s ethical quandaries.


Dr. Nicole Novroski is a forensic biologist in the Forensic Science Program, housed within the Department of Anthropology at the University of Toronto Mississauga. She is also the editor-in-chief of the Mary Anne Liebert journal Forensic Genomics.

Hosted on Acast. See acast.com/privacy for more information.

]]> In this episode, Nicole Novroski, PhD, examines the up-and-coming field of forensic genomics, covering everything from current and controversial forensic genomics research topics to mistakes and misconceptions about the field brought on by television and film and to some of the field’s ethical quandaries.


Dr. Nicole Novroski is a forensic biologist in the Forensic Science Program, housed within the Department of Anthropology at the University of Toronto Mississauga. She is also the editor-in-chief of the Mary Anne Liebert journal Forensic Genomics.

Hosted on Acast. See acast.com/privacy for more information.

]]> Human After All Human After All Fri, 11 Aug 2023 20:40:19 GMT 47:32 64d69cb3b4d0da001069411a false https://shows.acast.com/the-leading-strand/episodes/human-after-all 64d69cb3b4d0da001069411a 64d6996307d13c001124097d human-after-all Gene and cell therapy, gene editing, genomics, drug development, bioinformatics / computational biology full 1 3 Cued by the Mary Anne Liebert journal Human Gene Therapy, serial entrepeuneur and investor Nessan Bermingham, PhD, examines the state of human gene therapy, its future, and the technical, financial, and regulatory obstacles.


Nessan has founded multiple companies in the Life Sciences space, most notably, Intellia Therapeutics. Currently, Nessan is an Operating Partner at Khosla Ventures. He focuses on companies with an emphasis on nucleic acid editing, novel delivery systems, gene & cell therapy, novel target identification and data analytics for drug discovery and development. Nessan is trained as a scientist. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.



Hosted on Acast. See acast.com/privacy for more information.

]]> Cued by the Mary Anne Liebert journal Human Gene Therapy, serial entrepeuneur and investor Nessan Bermingham, PhD, examines the state of human gene therapy, its future, and the technical, financial, and regulatory obstacles.


Nessan has founded multiple companies in the Life Sciences space, most notably, Intellia Therapeutics. Currently, Nessan is an Operating Partner at Khosla Ventures. He focuses on companies with an emphasis on nucleic acid editing, novel delivery systems, gene & cell therapy, novel target identification and data analytics for drug discovery and development. Nessan is trained as a scientist. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.



Hosted on Acast. See acast.com/privacy for more information.

]]> Just A Phage Just A Phage Fri, 11 Aug 2023 20:36:36 GMT 45:44 64d69bd446c01600112e53de false https://shows.acast.com/the-leading-strand/episodes/just-a-phage 64d69bd446c01600112e53de 64d6996307d13c001124097d just-a-phage Infectious disease, viruses/bacteriophages, drug development, microbial resistance, genomics full 1 2 Martha Clokie, PhD, is focused on finding and developing bacteriophages that kill pathogens to make new antimicrobials. As a Professor of Microbiology at the University of Leicester, Dr. Clokie is focused on finding and developing bacteriophages that kill pathogens to make new antimicrobials. She is currently developing an alternative, phage-based treatment for Lyme disease and Clostridium difficile, a bacteria that can infect the bowel and cause diarrhea. Dr. Clokie is also studying how phages affect bacteria in the gut and how phages can be used to treat Salmonella in animals. She is also the editor in chief of the Mary Anne Liebert journal Phage.


In this episode, Dr. Clokie chews over what makes a phage a good candidate for a therapeutic, how genomics has changed the phage research landscape, and what challenges remain or stand in the way of making phage therapy accessible and routine.



Hosted on Acast. See acast.com/privacy for more information.

]]> Martha Clokie, PhD, is focused on finding and developing bacteriophages that kill pathogens to make new antimicrobials. As a Professor of Microbiology at the University of Leicester, Dr. Clokie is focused on finding and developing bacteriophages that kill pathogens to make new antimicrobials. She is currently developing an alternative, phage-based treatment for Lyme disease and Clostridium difficile, a bacteria that can infect the bowel and cause diarrhea. Dr. Clokie is also studying how phages affect bacteria in the gut and how phages can be used to treat Salmonella in animals. She is also the editor in chief of the Mary Anne Liebert journal Phage.


In this episode, Dr. Clokie chews over what makes a phage a good candidate for a therapeutic, how genomics has changed the phage research landscape, and what challenges remain or stand in the way of making phage therapy accessible and routine.



Hosted on Acast. See acast.com/privacy for more information.

]]> Take Me To Church Take Me To Church Fri, 11 Aug 2023 20:30:17 GMT 47:45 64d69a597d1ad2001125c33e false https://shows.acast.com/the-leading-strand/episodes/episode-1-take-me-to-church-f 64d69a597d1ad2001125c33e 64d6996307d13c001124097d episode-1-take-me-to-church-f Aging, astrobiology, DNA writing, genetic engineering, gene therapy full 1 1 This episode sees biotechnology through the eyes of George Church, PhD. In the academic world, Dr. Church is a Professor of Genetics at Harvard Medical School, a Professor of Health Sciences and Technology at Harvard University and MIT, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard. As a serial entrepreneur, Dr. Church has founded dozens of companies, and some of his most recent corporate endeavors include: de-extinction company Colossal Biosciences, personal genomics company Nebula Genomics, age-related disease company Rejuvenate Bio, xenotransplantation company E-genesis, and a newly unveiled astrobiology company named Copernicus Space Corporation.


In this episode, Dr. Church focuses on the reversal of age-related diseases, gene drives and other biotechnology ethical concerns, the potential of organismal DNA-based flight recorders, and what it takes for the visionary to get behind a project and take it from the lab and into the biotech industry. We also discuss Dr. Church’s recent review in the Mary Anne Liebert Journal Astrobiology on sending biological probes to space.



Hosted on Acast. See acast.com/privacy for more information.

]]> This episode sees biotechnology through the eyes of George Church, PhD. In the academic world, Dr. Church is a Professor of Genetics at Harvard Medical School, a Professor of Health Sciences and Technology at Harvard University and MIT, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard. As a serial entrepreneur, Dr. Church has founded dozens of companies, and some of his most recent corporate endeavors include: de-extinction company Colossal Biosciences, personal genomics company Nebula Genomics, age-related disease company Rejuvenate Bio, xenotransplantation company E-genesis, and a newly unveiled astrobiology company named Copernicus Space Corporation.


In this episode, Dr. Church focuses on the reversal of age-related diseases, gene drives and other biotechnology ethical concerns, the potential of organismal DNA-based flight recorders, and what it takes for the visionary to get behind a project and take it from the lab and into the biotech industry. We also discuss Dr. Church’s recent review in the Mary Anne Liebert Journal Astrobiology on sending biological probes to space.



Hosted on Acast. See acast.com/privacy for more information.

]]>